Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2330672 with Metformin in T2DM
NCT01929863Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2013
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of linerixibat in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by GSK. Primary endpoints: Number of Participants With at Least One Adverse Event (AE), Serious Adverse Event (SAE) or Death up to 53 days, Number of Participants With the Indicated Clinical Chemistry Values of Potential Clinical Importance (PCI) up to 53 days and 6 more. Started Aug 2013; status: completed.
02
Drugs
linerixibat
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01929863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01929863.